Developing Targeted Therapies That Exploit Aberrant Histone Ubiquitination in Cancer

Cells

KirkJ McManus¹  LucileM-P Jeusset² 

[1] Medical Genetics, University of Manitoba, Winnipeg, MB R3E 0J9, Canada;;Department of Biochemistry &

关键词: histone;    H2A;    H2B;    ubiquitination;    deubiquitination;    E3 ubiquitin ligase;    cancer;    epigenetic therapy;    synthetic lethality;    epigenome editing;   

DOI  :  10.3390/cells8020165

来源: DOAJ

【 摘 要 】

Histone ubiquitination is a critical epigenetic mechanism regulating DNA-driven processes such as gene transcription and DNA damage repair. Importantly, the cellular machinery regulating histone ubiquitination is frequently altered in cancers. Moreover, aberrant histone ubiquitination can drive oncogenesis by altering the expression of tumor suppressors and oncogenes, misregulating cellular differentiation and promoting cancer cell proliferation. Thus, targeting aberrant histone ubiquitination may be a viable strategy to reprogram transcription in cancer cells, in order to halt cellular proliferation and induce cell death, which is the basis for the ongoing development of therapies targeting histone ubiquitination. In this review, we present the normal functions of histone H2A and H2B ubiquitination and describe the role aberrant histone ubiquitination has in oncogenesis. We also describe the key benefits and challenges associated with current histone ubiquitination targeting strategies. As these strategies are predicted to have off-target effects, we discuss additional efforts aimed at developing synthetic lethal strategies and epigenome editing tools, which may prove pivotal in achieving effective and selective therapies targeting histone ubiquitination, and ultimately improving the lives and outcomes of those living with cancer.

【 授权许可】

Unknown